Suntrust Banks Inc. cut its holdings in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 32.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,050 shares of the medical research company’s stock after selling 1,934 shares during the quarter. Suntrust Banks Inc.’s holdings in PAREXEL International Corporation were worth $351,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. World Asset Management Inc increased its holdings in PAREXEL International Corporation by 0.3% during the 2nd quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after purchasing an additional 9 shares during the last quarter. Amalgamated Bank increased its holdings in PAREXEL International Corporation by 0.6% during the 2nd quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock worth $631,000 after purchasing an additional 42 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in PAREXEL International Corporation by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after purchasing an additional 73 shares during the last quarter. Texas Permanent School Fund increased its holdings in PAREXEL International Corporation by 0.5% during the 2nd quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock worth $3,221,000 after purchasing an additional 169 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in PAREXEL International Corporation by 10.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after purchasing an additional 180 shares during the last quarter. Institutional investors own 87.45% of the company’s stock.

PAREXEL International Corporation (NASDAQ:PRXL) opened at 88.08 on Friday. The firm’s 50-day moving average price is $87.85 and its 200-day moving average price is $79.27. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $88.10. The firm has a market cap of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77.

PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. The firm had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the firm posted $0.94 EPS. Equities research analysts predict that PAREXEL International Corporation will post $4.06 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Suntrust Banks Inc. Has $351,000 Holdings in PAREXEL International Corporation (PRXL)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/10/14/suntrust-banks-inc-has-351000-holdings-in-parexel-international-corporation-prxl.html.

Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded PAREXEL International Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Barclays PLC downgraded PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target for the company. in a report on Tuesday, June 20th. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Jefferies Group LLC reiterated a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Finally, BidaskClub downgraded PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. PAREXEL International Corporation has a consensus rating of “Hold” and a consensus target price of $75.92.

PAREXEL International Corporation Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.